PF-804

PF-804 is an investigational small molecule drug developed as a targeted therapy for non-small cell lung cancer (NSCLC). It is described in patient and clinical trial discussions as a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, sometimes referred to as "super Tarceva" due to its intended activity against EGFR mutations that confer resistance to first-generation EGFR inhibitors. The drug was under clinical investigation at major cancer centers, such as Princess Margaret Hospital in Toronto, for patients with advanced or treatment-resistant NSCLC[6]. Its mechanism of action involves inhibiting the EGFR tyrosine kinase pathway, which plays a critical role in the proliferation and survival of certain lung cancer cells.